The African Union (AU) has dropped plans to secure coronavirus vaccines from the Serum Institute of India because of supply concerns and is instead exploring options with the US drugmaker, Johnson & Johnson. The head of Africa’s Centres for Disease Control, John Nkengasong, said reliable supplies of vaccines were vital – and that Indian restrictions on exports had complicated things for Africa. He added that the AU’s decision had nothing to do with the possible link to blood clots in rare cases involving the Oxford-AstraZeneca vaccine which will still be supplied to Africa through the UN’s Covax scheme. India’s Serum Institute is licensed to make global supplies of AstraZeneca but Delhi has commandeered stocks to deal with surging infections. Mr Nkengasong said the AU had already signed a deal for up to 400 million single dose jabs from Johnson & Johnson.
SOURCE: BBC
More Stories
Can Africa’s Green Initiatives Mitigate Effects of Climate Change?
Damning Allegations Levelled against British American Tobacco South Africa
How Kenyan Airways Pivoted to Meet New Market Shift
Seven Africans Make Time Magazine’s List of the 100 Most Influential People in the World for 2021
Benin is the Fastest Place in the World to Start a Company
Tech SME Gains Business Success, Growth And Acquisition During The Pandemic
The Number of Children Working Across Mines in Africa is Rising
A Startup that Will Cut the Cost it Takes to Produce Palm Oil
Africa to Pull Out All the Stops at Dubai’s World Expo
Somalia is on the Cusp of Becoming the World’s First Cashless Society
A Mission to Rehabilitate Nigeria’s Waterways One Beach at a Time
Dumpster Diving on the Rise Among Ghanaian Kids